Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year

OBJECTIVES: The safety and efficacy of subcutaneous golimumab through 2 years of maintenance therapy was evaluated in patients with moderate-to-severe ulcerative colitis (UC). METHODS: Patients completing treatment through week 52 (placebo, golimumab 50, 100, every-4-weeks (q4w)) and evaluations at...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, Peter R, Feagan, Brian G, Sandborn, William J, Marano, Colleen, Strauss, Richard, Johanns, Jewel, Padgett, Lakshmi, Collins, Judith, Tarabar, Dino, Hebzda, Zbigniew, Rutgeerts, Paul, Reinisch, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855165/
https://www.ncbi.nlm.nih.gov/pubmed/27124701
http://dx.doi.org/10.1038/ctg.2016.24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855165/
https://www.ncbi.nlm.nih.gov/pubmed/27124701
http://dx.doi.org/10.1038/ctg.2016.24

Ejemplares similares